Renalytix AI PLC ADR (RNLX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNLX Stock Price Chart Interactive Chart >
RNLX Price/Volume Stats
| Current price | $19.80 | 52-week high | $35.71 |
| Prev. close | $18.01 | 52-week low | $9.91 |
| Day low | $17.99 | Volume | 166,600 |
| Day high | $19.82 | Avg. volume | 116,874 |
| 50-day MA | $26.72 | Dividend yield | N/A |
| 200-day MA | $25.84 | Market Cap | 715.08M |
Renalytix AI PLC ADR (RNLX) Company Bio
Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded on March 15,2018 and is headquartered in Penarth, the United Kingdom.
Latest RNLX News From Around the Web
Below are the latest news stories about Renalytix plc that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning, investor! |
Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care ModelTargeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™ early-stage risk assessment testing and care management program across primary care and specialty clinician networks under a real-world evidence development program for patients with diabetic kidney diseas |
3 High-Growth Healthcare Stocks to Buy in SeptemberAll three are rapidly expanding into their own corners of America's $4 trillion per year healthcare sector. |
Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare ConferenceNEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (Renalytix or the Company) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. |
Renalytix Appoints Daniel J. Levangie to its Board of DirectorsLevangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic |
RNLX Price Returns
| 1-mo | -22.57% |
| 3-mo | -38.13% |
| 6-mo | -29.79% |
| 1-year | 52.19% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 23.75% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...